ATE524195T1 - Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen - Google Patents

Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen

Info

Publication number
ATE524195T1
ATE524195T1 AT02726561T AT02726561T ATE524195T1 AT E524195 T1 ATE524195 T1 AT E524195T1 AT 02726561 T AT02726561 T AT 02726561T AT 02726561 T AT02726561 T AT 02726561T AT E524195 T1 ATE524195 T1 AT E524195T1
Authority
AT
Austria
Prior art keywords
protein
clfa
monoclonal antibodies
treatment
infections
Prior art date
Application number
AT02726561T
Other languages
English (en)
Inventor
Joseph M Patti
Jeff T Hutchins
Paul Domanski
Pratisksha Patel
Andrea Hall
Original Assignee
Inhibitex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibitex Inc filed Critical Inhibitex Inc
Application granted granted Critical
Publication of ATE524195T1 publication Critical patent/ATE524195T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT02726561T 2001-01-26 2002-01-28 Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen ATE524195T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26407201P 2001-01-26 2001-01-26
US27461101P 2001-03-12 2001-03-12
US29841301P 2001-06-18 2001-06-18
US30811601P 2001-07-30 2001-07-30
PCT/US2002/002296 WO2002072600A2 (en) 2001-01-26 2002-01-28 Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections

Publications (1)

Publication Number Publication Date
ATE524195T1 true ATE524195T1 (de) 2011-09-15

Family

ID=27500806

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02726561T ATE524195T1 (de) 2001-01-26 2002-01-28 Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen

Country Status (15)

Country Link
US (2) US6979446B2 (de)
EP (1) EP1377314B1 (de)
JP (1) JP4171816B2 (de)
KR (2) KR20030071861A (de)
CN (2) CN101928343B (de)
AT (1) ATE524195T1 (de)
AU (1) AU2002256985B8 (de)
BR (1) BR0207068A (de)
CA (1) CA2434762A1 (de)
DK (1) DK1377314T3 (de)
ES (1) ES2372686T3 (de)
IL (2) IL157041A0 (de)
MX (1) MXPA03006651A (de)
PT (1) PT1377314E (de)
WO (1) WO2002072600A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994855B1 (en) * 1994-08-22 2006-02-07 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US6692739B1 (en) * 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
ZA200503075B (en) 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
WO2006138627A2 (en) * 2005-06-16 2006-12-28 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
CA2637152A1 (en) * 2006-01-27 2007-08-09 Merck & Co., Inc. Antigen-binding proteins targeting s. aureus orf0657n
EP1996231A4 (de) * 2006-02-22 2010-09-15 Texas A & M Univ Sys Antikörper mit stark expressierter putativer antigenerkennung von ca-mrsa und verwendungsverfahren
JP2010510524A (ja) * 2006-11-22 2010-04-02 スリーエム イノベイティブ プロパティズ カンパニー 試料を調製及び分析するシステム並びに方法
US20100062418A1 (en) * 2006-11-22 2010-03-11 Mach Patrick A Inactivated and dried biological preparations
US20100129837A1 (en) * 2006-11-22 2010-05-27 Mach Patrick A Methods of capturing bacterial whole cells and methods of analyzing samples for bacteria
US8597959B2 (en) * 2007-04-19 2013-12-03 3M Innovative Properties Company Methods of use of solid support material for binding biomolecules
US20100209946A1 (en) * 2007-04-19 2010-08-19 Naiyong Jing Uses of water-dispersible silica nanoparticles for attaching biomolecules
WO2009029132A2 (en) * 2007-05-31 2009-03-05 Merck & Co., Inc. Antigen-binding proteins targeting s. aureus orf0657n
EP2220500A4 (de) * 2007-11-20 2010-12-15 3M Innovative Properties Co Verfahren zur analyse einer probe für ein bakterium unter verwendung eines diacetylenhaltigen polymersensors
CN101952729A (zh) * 2008-02-20 2011-01-19 3M创新有限公司 利用全细胞捕获和atp分析进行样品细菌分析的方法
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
JP6192294B2 (ja) 2009-07-15 2017-09-06 エーアイエムエム セラピューティクス ベー．フェー． グラム陽性菌特異的結合化合物
US8163283B2 (en) * 2009-09-03 2012-04-24 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
SG10201407757XA (en) 2009-10-23 2015-01-29 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
JP6018917B2 (ja) 2009-12-07 2016-11-02 デシミューン セラピューティクス，インコーポレイテッド 抗炎症抗体およびその使用
EP3604339B1 (de) 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutische antikörper gegen das ror-1-protein und verfahren zur verwendung davon
KR101044438B1 (ko) * 2011-03-29 2011-06-27 최희선 저수탱크
WO2013012743A2 (en) * 2011-07-15 2013-01-24 The University Of Chicago Methods and compositions for inhibiting staphylococcus agglutination in blood
JP2014534169A (ja) * 2011-09-23 2014-12-18 ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクＪｕｌｉｕｓ Ｍａｘｉｍｉｌｉａｎｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｗｕｅｒｚｂｕｒｇ Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓエピトープ結合部位を形成するペプチドまたはペプチドの配置
US8834898B2 (en) 2011-12-16 2014-09-16 Boise State University Cholera toxin chimera and its use as a staph vaccine
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
AU2013251312B2 (en) 2012-04-27 2018-03-22 Takeda Pharmaceutical Company Limited Anti-GCC antibody molecules and use of same to test for susceptibility to GCC-targeted therapy
EP2705852A1 (de) * 2012-09-06 2014-03-12 Université de Lausanne Immunogene Zusammensetzung gegen Staphylococcus aureus, umfassend ein inaktiviertes rekombinantes nicht pathogenes Bakterium
BR112015010125A2 (pt) * 2012-11-06 2017-08-22 Medimmune Llc Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
WO2014165115A1 (en) 2013-03-12 2014-10-09 Decimmune Therapeutics, Inc. Humanized anti-n2 antibodies
HUE049292T2 (hu) 2013-08-07 2020-09-28 Yeda Res & Dev A P53 mutánsok újraaktíválására képes peptidek
CA2932819A1 (en) 2013-12-09 2015-06-18 New York University Compositions and methods for phagocyte delivery of anti-staphylococcal agents
US11446371B2 (en) * 2015-11-05 2022-09-20 The Texas A&M University System Targeting of ligand binding sites in ClfA
CN108884137B (zh) 2016-02-04 2022-04-05 耶达研究及发展有限公司 肽及其在治疗与突变型p53相关的疾病、病症或病况中的用途
WO2017198731A1 (en) 2016-05-18 2017-11-23 Genmab B.V. Antibodies and methods of use thereof in treatment of infectious disease
US11155608B2 (en) * 2017-08-23 2021-10-26 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against pathological alpha-synuclein, and methods using same
EP3784776A4 (de) * 2018-05-23 2022-01-26 National University of Singapore Blockade der cd2-oebrflächenexpression und expression chimärer antigenrezeptoren für die immuntherapie von t-zell-malignomen
CN110632298B (zh) * 2018-06-25 2023-04-18 洛阳普泰生物技术有限公司 犬腺病毒1型单克隆抗体、可变区序列、杂交瘤细胞株及其应用
JP7525471B2 (ja) 2018-07-24 2024-07-30 メディミューン，エルエルシー Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体
BR112021006622A2 (pt) 2018-10-09 2021-07-20 Medimmune, Llc combinações de anticorpos anti-staphylococcus aureus
KR20210126641A (ko) 2019-02-12 2021-10-20 리제너론 파아마슈티컬스, 인크. 보체 및 표적 항원에 결합하기 위해 이중 특이적 항체를 사용하는 조성물 및 방법
WO2020243616A1 (en) * 2019-05-31 2020-12-03 Seattle Children's Hospital D/B/A Seattle Children's Research Institute E-cadherin activating antibodies and uses thereof
WO2024237730A1 (ko) * 2023-05-18 2024-11-21 한국과학기술연구원 항-엔도글린 항체 및 이의 용도
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same
CN118406141B (zh) * 2024-04-25 2024-11-22 中国人民解放军总医院第四医学中心 一种抗金黄葡萄球菌胞外黏着蛋白的纳米抗体及其衍生产品和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK219084D0 (da) 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
US5240833A (en) * 1989-01-30 1993-08-31 The Biomembrane Institute Method for the production of monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US5256542A (en) * 1992-03-09 1993-10-26 Tanox Biosystems, Inc. Selecting low frequency antigen-specific single B lymphocytes with correction for background noise
ZA936260B (en) 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
EP0680337A4 (de) 1993-01-12 1997-07-30 Anthony George Gristina Methoden und zusammensetzungen zur direkter konzentrierter verabreichung passiver immunität.
DK0749321T3 (da) * 1994-02-09 2007-03-12 Epitopix Llc Aktiv immunisering under anvendelse af et sideroforreceptorprotein
US5648240A (en) 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
EP0781847A1 (de) * 1995-11-06 1997-07-02 MERCK PATENT GmbH Humanisierter monoklonaler Antikörper
DE69734601T2 (de) * 1996-05-16 2006-08-03 The Texas A & M University System, College Station Zusammensetzung von kollagenbindungsprotein und verfahren zu deren verwendungen
SE9704141D0 (sv) 1997-11-12 1997-11-12 Sbl Vaccin Ab New protein and nucleotide sequence, encoding said protein
EP1121149A4 (de) * 1998-08-31 2002-03-20 Inhibitex Inc Immunotherapeutika gegen staphylokokkus mittels donor selektion und donor stimulation
AU1157100A (en) 1998-10-29 2000-05-22 Connex Gmbh Detection of acid-resistant micro-organisms in a stool
AU4810600A (en) 1999-04-28 2000-11-10 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin, The Method of inhibiting leukocyte adhesion to fibrinogen

Also Published As

Publication number Publication date
EP1377314A4 (de) 2005-05-11
AU2002256985B2 (en) 2007-10-11
EP1377314A2 (de) 2004-01-07
WO2002072600A3 (en) 2003-11-06
US20030099656A1 (en) 2003-05-29
KR101015496B1 (ko) 2011-02-22
JP2004534000A (ja) 2004-11-11
DK1377314T3 (da) 2011-12-12
CN101928343A (zh) 2010-12-29
CN1489474A (zh) 2004-04-14
PT1377314E (pt) 2012-01-02
US7364738B2 (en) 2008-04-29
CN101928343B (zh) 2014-09-17
US6979446B2 (en) 2005-12-27
IL157041A0 (en) 2004-02-08
ES2372686T3 (es) 2012-01-25
JP4171816B2 (ja) 2008-10-29
AU2002256985B8 (en) 2008-03-20
CA2434762A1 (en) 2002-09-19
EP1377314B1 (de) 2011-09-14
KR20030071861A (ko) 2003-09-06
BR0207068A (pt) 2004-12-21
KR20090039851A (ko) 2009-04-22
US20050287164A1 (en) 2005-12-29
IL157041A (en) 2010-05-31
MXPA03006651A (es) 2004-11-12
WO2002072600A2 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
ATE524195T1 (de) Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen
ATE409181T1 (de) Proteomimetische verbindungen und verfahren
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
MY151199A (en) Substituted diphenyl heterocycles useful for treating hcv infection
DE69940404D1 (de) Multikomponenten Impfstoffe gegen Staphylococcus aureus
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
ATE427116T1 (de) Behandlung von bakteriellen infektionen
ATE362374T1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
ATE458750T1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
EA202192454A1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
WO2022011110A3 (en) Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
BRPI0410967A (pt) compostos, composições e seus usos para o tratamento de infecções por vìrus da famìlia flaviviridae
DE60134881D1 (de) Monoklonale antikörper gegen das map-protein und verfahren zu dessen anwendung bei der behandlung bzw. prävention von infektionen
WO2005010167A3 (en) Antibodies to the fbsa protein of streptococcus agalactiae and their use in treating or preventing infections
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE313628T1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
WO2023014970A3 (en) Nora inhibitors and methods of use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1377314

Country of ref document: EP